Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
David Son*
Phenobarbital and Cutco are two compounds with distinct pharmacological properties and potential effects on liver function. Understanding their comparative pharmacoproteomics profiles in human primary hepatocytes can provide valuable insights into their mechanisms of action and hepatotoxicity. In this study, we aimed to investigate the proteomic alterations induced by Phenobarbital and Cutco in human primary hepatocytes and compare their effects on protein expression, post-translational modifications, and protein-protein interactions. Through advanced proteomic techniques, we identified potential drug targets and biomarkers associated with the hepatotoxic effects of these compounds. Our findings contribute to a deeper understanding of the molecular mechanisms underlying their pharmacological activities and hepatic toxicity.